Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05320523
Other study ID # 38865720.1.0000.0068
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 20, 2021
Est. completion date January 2024

Study information

Verified date October 2021
Source University of Sao Paulo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1 study evaluating the safety of combined bilateral globus pallidus internus (GPi) and nucleus basalis of Meynert (NBM) stimulation in treating levodopa responsive motor symptoms of Parkinsonism and cognitive dysfunction, respectively, in patients with moderate to advanced Parkinson's disease having mild cognitive impairment.


Description:

This study aims to provide a proof of safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease having mild cognitive impairment. GPi stimulation with high-frequency ameliorates the cardinal motor symptoms and motor complications in Parkinson's disease patients, and this present study also wants to determine if additional NBM stimulation, with low-frequency stimulation, improves or slows progression of cognitive decline in patients with moderate to advanced Parkinson's disease having mild cognitive impairment, and to evaluate the effect of NBM stimulation on gait and balance impairment. Study Design: Prospective single center Phase 1 study with double-blind randomized delayed activation of basal nucleus of Meynert neurostimulation (staggered onset design). Planned Number of Subjects: 10 patients. Planned Number of Sites / Countries: Single center in Brazil. Study schedule: - Presurgical baseline evaluation (motor on and off medication state; cognitive testing in best motor on state). - DBS Implant Procedure. - Postsurgical baseline evaluation (motor off state; cognitive testing in best motor on state) at 3±1 weeks after surgery and activation of globus pallidus internus neurostimulation using individualized stimulation parameters after a standard monopolar review. - Regular adjustments of the GPi stimulation parameters aiming at the best motor improvement. - Visit 1 (16 weeks after activation of GPi neurostimulation): motor off medication + GPi stimulation state, cognitive testing in on medication + GPi stimulation state. Randomization and blinded activation of NBM neurostimulation according to a 1:1 scheme. - Visit 2 (16 weeks after randomization): motor off and on medication + stimulation state (GPi stimulation ± NBM stimulation); cognitive testing in motor on medication + stimulation state (GPi stimulation ± NBM stimulation). Activation of NBM neurostimulation in all patients. - Visit 3 (16 weeks after activation of NBM stimulation in all patients): motor off and on medication + GPi and NBM stimulation state; cognitive testing in motor on medication + GPi and NBM stimulation state. - Annual follow-up visit for up to 5 years after activation of NBM stimulation.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date January 2024
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Age at the time of enrollment: 50 - 75 years. - Diagnosis of idiopathic PD according to Movement Disorders Society (MDS) criteria (Albanese et al., 2017). - Mild cognitive impairment (MCI) related to Parkinson's disease according to MDS criteria. (Livtan et al. 2012). - Duration of bilateral idiopathic PD: = 5 years of motor symptoms. - Modified Hoehn and Yahr stage = 2 on off medication state. - UPDRS subset III (motor) = 30 points on off medication state. - Levodopa must improve PD symptoms by = 30% in a levodopa challenge test, as measured by UPDRS subset III score. - Presence of motor complications related to Parkinson's disease. - Be willing and able to comply with all visits and study related procedures - Able to understand the study requirements and the treatment procedures and to provide written informed consent before any study-specific tests or procedures are performed. Exclusion Criteria: - Alcohol or drug abuse. - Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression. - Contraindications for deep brain stimulation (DBS) surgery. - Heart failure, heart disease or any condition that contraindicates surgical procedures. - Pacemaker or other active implanted stimulators. - Clearly established Parkinson's disease dementia according to Movement Disorders Criteria. - Participation in another drug, device, or biologics trial concurrently.

Study Design


Intervention

Device:
Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.
Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
GPi stimulation
Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
NBM stimulation
Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
Sham stimulation
Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system

Locations

Country Name City State
Brazil University of São Paulo General Hospital São Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

References & Publications (10)

Dalrymple WA, Huss DS, Blair J, Flanigan JL, Patrie J, Sperling SA, Shah BB, Harrison MB, Druzgal TJ, Barrett MJ. Cholinergic nucleus 4 atrophy and gait impairment in Parkinson's disease. J Neurol. 2021 Jan;268(1):95-101. doi: 10.1007/s00415-020-10111-2. — View Citation

Freund HJ, Kuhn J, Lenartz D, Mai JK, Schnell T, Klosterkoetter J, Sturm V. Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch Neurol. 2009 Jun;66(6):781-5. doi: 10.1001/archneurol.2009.102. Erratum i — View Citation

Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T. Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease De — View Citation

Gratwicke J, Zrinzo L, Kahan J, Peters A, Brechany U, McNichol A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Crutch SJ, Taylor JP, McKeith I, Rochester L, Schott JM, Limousin P, Burn D, Rossor MN, Hariz M, Jahanshahi M, Fol — View Citation

Koulousakis P, Andrade P, Visser-Vandewalle V, Sesia T. The Nucleus Basalis of Meynert and Its Role in Deep Brain Stimulation for Cognitive Disorders: A Historical Perspective. J Alzheimers Dis. 2019;69(4):905-919. doi: 10.3233/JAD-180133. Review. — View Citation

Kuhn J, Hardenacke K, Lenartz D, Gruendler T, Ullsperger M, Bartsch C, Mai JK, Zilles K, Bauer A, Matusch A, Schulz RJ, Noreik M, Bührle CP, Maintz D, Woopen C, Häussermann P, Hellmich M, Klosterkötter J, Wiltfang J, Maarouf M, Freund HJ, Sturm V. Deep br — View Citation

Müller ML, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep. 2013 Sep;13(9):377. doi: 10.1007/s11910-013-0377-9. Review. — View Citation

Nombela C, Lozano A, Villanueva C, Barcia JA. Simultaneous Stimulation of the Globus Pallidus Interna and the Nucleus Basalis of Meynert in the Parkinson-Dementia Syndrome. Dement Geriatr Cogn Disord. 2019;47(1-2):19-28. doi: 10.1159/000493094. Epub 2019 — View Citation

Sankar T, Lipsman N, Lozano AM. Deep brain stimulation for disorders of memory and cognition. Neurotherapeutics. 2014 Jul;11(3):527-34. doi: 10.1007/s13311-014-0275-0. Review. — View Citation

Wilson J, Yarnall AJ, Craig CE, Galna B, Lord S, Morris R, Lawson RA, Alcock L, Duncan GW, Khoo TK, O'Brien JT, Burn DJ, Taylor JP, Ray NJ, Rochester L. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Mov Disord. 2021 Mar; — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events. Safety of combined bilateral GPi and NBM stimulation in patients with moderate to advanced Parkinson's disease having mild cognitive impairment as determined by reported adverse events. 36 weeks
Secondary Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS). This scale can range from 0 to 134, and higher scores mean a better outcome. 36 weeks
Secondary Change in Mattis Dementia Rating Scale. This scale can range from 0 to 144, and higher scores mean a better outcome. 36 weeks
Secondary Change in Verbal Fluency Battery. FAS and animals 36 weeks
Secondary Change in Trail Making Task. Trail Making Task Part A + B. 36 weeks
Secondary Change in Stroop Test. Stroop Test (Victoria Version). 36 weeks
Secondary Change in Symbol Digit Modalities Test. Digit symbol coding - WAIS. 36 weeks
Secondary Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39). This questionnaire can range from 0 to 100%, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Questionnaire of the EuroQol-group (EQ-5D-5L). This questionnaire can range from 0 to 25, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I). This scale can range from 0 to 52, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Unified Parkinson's Disease Rating Scale section II (UPDRS II). This scale can range from 0 to 52, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Unified Parkinson's Disease Rating Scale section III (UPDRS III). This scale can range from 0 to 132, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV). This scale can range from 0 to 24, and higher scores mean a worse outcome. 36 weeks
Secondary Change in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed. 36 weeks
Secondary Change in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute. 36 weeks
Secondary Change in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels. 36 weeks
Secondary Change in objective assessment of gait measured by a sensor (MobilityLab) that assess balance. 36 weeks
Secondary Change in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M). 36 weeks
Secondary Change in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M). 36 weeks
Secondary Change in objective assessment of gait measured by freezing of gait score (FOG score). 36 weeks
Secondary Change in New Freezing of Gait Questionnaire (N-FOG). This questionnaire can range from 0 to 28, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Falls Efficacy Scale International (FES-I). This questionnaire can range from 0 to 64, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Activities-Specific Balance Confidence Scale (ABC scale). This scale can range from 0 to 100%, and higher scores mean a better outcome. 36 weeks
Secondary Change in Beck Depression Inventory (BDI). This inventory can range from 0 to 63, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Beck Anxiety Inventory (BAI). This inventory can range from 0 to 63, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Starkstein Apathy Scale. This scale can range from 0 to 42, and higher scores mean a worse outcome. 36 weeks
Secondary Change in Neuropsychiatric Inventory (NPI). 36 weeks
Secondary Change in Ardouin Scale of Behavior in Parkinson's Disease. This scale can range from 0 to 84, and higher scores mean a worse outcome. 36 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A